Answers are grounded in this paper and cite their sources.
This research demonstrates programmable bioconjugates enhancing biomarker detection in proteomic assays, implying better diagnostics.
Front Cover The image illustrates programmable dual-targeting nano-bioconjugates formed by assembling bispecific antibody fragments (BsAbs) on PEGylated nanoparticle clusters. BsAbs enable precise dual recognition at the single-molecule level, demonstrating the specificity and modularity of this strategy. Controlled BsAb-F conjugation on mPEG nanoparticles improves SERS-based biosensing for ultrasensitive, multiplexed biomarker detection and supports broader applications in functional nanomaterial design. More in article number e01235, Alain Wuethrich, Christopher B. Howard, Matt Trau, and co-workers.
No takes yet. Share an insight, caveat, or question.
Farokhinejad et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: